2.76
price down icon1.43%   -0.04
after-market After Hours: 2.74 -0.02 -0.72%
loading
Regulus Therapeutics Inc stock is traded at $2.76, with a volume of 897.96K. It is down -1.43% in the last 24 hours and up +112.31% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$2.80
Open:
$2.82
24h Volume:
897.96K
Relative Volume:
0.76
Market Cap:
$133.15M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-1.7468
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
+33.98%
1M Performance:
+112.31%
6M Performance:
+91.67%
1Y Performance:
+21.59%
1-Day Range:
Value
$2.6603
$2.85
1-Week Range:
Value
$1.975
$2.90
52-Week Range:
Value
$0.8301
$2.90

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Name
Regulus Therapeutics Inc
Name
Phone
858-202-6300
Name
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Employee
34
Name
Twitter
@regulusrx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
RGLS's Discussions on Twitter

Compare RGLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RGLS
Regulus Therapeutics Inc
2.76 133.15M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-25 Upgrade Wells Fargo Equal Weight → Overweight
Aug-02-24 Initiated Oppenheimer Outperform
Mar-18-24 Initiated Leerink Partners Outperform
Mar-28-18 Initiated B. Riley FBR, Inc. Neutral
Jan-05-18 Initiated Leerink Partners Outperform
Jun-13-17 Reiterated Chardan Capital Markets Buy
Mar-06-17 Reiterated Wedbush Outperform
Jan-30-17 Downgrade Needham Buy → Hold
Jan-30-17 Downgrade Wells Fargo Outperform → Market Perform
Dec-07-16 Reiterated Chardan Capital Markets Buy
Nov-02-16 Reiterated Needham Buy
Jul-25-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated FBR Capital Outperform
Jun-28-16 Reiterated Needham Buy
Jun-07-16 Reiterated Chardan Capital Markets Buy
Apr-13-16 Initiated Chardan Capital Markets Buy
Dec-04-15 Initiated Wells Fargo Outperform
Jun-09-15 Initiated Guggenheim Buy
Apr-21-15 Resumed FBR Capital Outperform
Nov-24-14 Initiated Deutsche Bank Buy
Aug-07-14 Reiterated FBR Capital Outperform
Aug-14-13 Reiterated Needham Buy
View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

pulisher
Apr 25, 2025

Does Regulus Therapeutics Inc (NASDAQ:RGLS) Look Expensive At $2.80? Here’s How To Know. - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 24, 2025

Should You Buy Regulus (RGLS) After Golden Cross? - Yahoo

Apr 24, 2025
pulisher
Apr 23, 2025

Regulus Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Regulus Therapeutics Inc (RGLS) Stock: Navigating a Year of Volatility - investchronicle.com

Apr 23, 2025
pulisher
Apr 23, 2025

Plus Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.0899: Will the Stock Break Through? - investchronicle.com

Apr 23, 2025
pulisher
Apr 23, 2025

Analytical Overview: Regulus Therapeutics Inc (RGLS)’s Ratios Tell a Financial Story - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Taking the lead: Regulus Therapeutics Inc (RGLS) - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

A closer look at Regulus Therapeutics Inc (RGLS)’s stock price trends - uspostnews.com

Apr 22, 2025
pulisher
Apr 18, 2025

10 Best Rising Penny Stocks to Buy According to Analysts - Insider Monkey

Apr 18, 2025
pulisher
Apr 18, 2025

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey

Apr 18, 2025
pulisher
Apr 12, 2025

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average – Time to Sell? - Defense World

Apr 12, 2025
pulisher
Apr 04, 2025

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - Longview News-Journal

Apr 02, 2025
pulisher
Apr 02, 2025

microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan

Apr 02, 2025
pulisher
Mar 31, 2025

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st

Mar 31, 2025
pulisher
Mar 29, 2025

Regulus Therapeutics (NASDAQ:RGLS) Raised to “Overweight” at Wells Fargo & Company - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Announces Positive Phase 1b Study Results - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 23, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World

Mar 23, 2025
pulisher
Mar 18, 2025

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World

Mar 16, 2025
pulisher
Mar 16, 2025

10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey

Mar 16, 2025
pulisher
Mar 15, 2025

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo

Mar 15, 2025
pulisher
Mar 15, 2025

Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

H.C. Wainwright maintains Buy on Regulus stock, $10 target - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus: Q4 Earnings Snapshot - San Antonio Express-News

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Mar 11, 2025
pulisher
Mar 04, 2025

AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart

Mar 04, 2025
pulisher
Mar 04, 2025

AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR

Mar 04, 2025
pulisher
Mar 04, 2025

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - Stock Titan

Mar 04, 2025

Regulus Therapeutics Inc Stock (RGLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):